Bridgeway Capital Management’s Climb Bio CLYM Stock Holding History

Bridgeway Capital Management’s Portfolio CLYM Stock Details CLYM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$920K	Sell	134,300 -25,000	-16%	-$144K	0.02%	720
2025 Q4	$637K	Buy	159,300 +50,000	+46%	+$120K	0.01%	780
2025 Q3	$220K	Sell	109,300 -25,000	-19%	-$46.4K	﹤0.01%	997
2025 Q2	$167K	Hold	134,300	–	–	﹤0.01%	996
2025 Q1	$164K	Buy	+134,300	New	+$218K	﹤0.01%	958
2024 Q3	–	Sell	-55,223	Closed	-$393K	–	1327
2024 Q2	$393K	Hold	55,223	–	–	0.01%	917
2024 Q1	$151K	Hold	55,223	–	–	﹤0.01%	1152
2023 Q4	$148K	Hold	55,223	–	–	﹤0.01%	1188
2023 Q3	$146K	Hold	55,223	–	–	﹤0.01%	1153
2023 Q2	$155K	Hold	55,223	–	–	﹤0.01%	1184
2023 Q1	$160K	Hold	55,223	–	–	﹤0.01%	1142
2022 Q4	$198K	Hold	55,223	–	–	0.01%	1092
2022 Q3	$178K	Buy	55,223 +34,800	+170%	+$111K	﹤0.01%	1161
2022 Q2	$62K	Buy	20,423 +2,023	+11%	+$9.57K	﹤0.01%	1272
2022 Q1	$154K	Buy	+18,400	New	+$172K	﹤0.01%	1210

Other funds holding CLYM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Bridgeway Capital Management's CLYM Position: Q1 2026 in Review

Bridgeway Capital Management reduced its Climb Bio (CLYM) stake by 16% in Q1 2026, selling an estimated $144K and leaving 134,300 shares worth $920K. The position accounts for 0.02% of the portfolio, ranked #720.

Bridgeway Capital Management first reported a position in CLYM in Q1 2022 and has held it in 15 quarters since. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

Bridgeway Capital Management held 134,300 shares of Climb Bio worth $920K as of Q1 2026.
Bridgeway Capital Management sold 25,000 Climb Bio shares in Q1 2026, an estimated $144K.
Climb Bio made up 0.02% of Bridgeway Capital Management's portfolio in Q1 2026, its #720 holding.
Bridgeway Capital Management first reported a position in Climb Bio in Q1 2022 and has held it in 15 quarters since.
80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.